Your CEO just mandated AI adoption. Here's the five-line memo your chief of QA-RA actually needs.

TL;DR

The CEO came back from a conference and wants an AI strategy for quality. The deputy quality lead is the one writing it.

Most first drafts read like vendor brochures, hedge with "exploring," or overpromise on timeline. None of those land with the board.

The honest version is 5 lines: 1 capability shipped, 1 pilot named, 1 thing you're explicitly not doing, your data integrity approach, and what you'll know by the next board meeting.

The scene

Your CEO returns from a top industry conference. Every panel mentioned AI.

Every dinner conversation mentioned AI.

The AI question lands on the head of quality. The head looks at the deputy.

The deputy has a week.

This is the literal moment every quality and regulatory team in 2026 is dealing with.

The AI confidence gap in pharma quality

BCG's January 2026 AI Radar found that 9 of 10 CEOs feel they could speak knowledgeably about AI.

Gartner found 88% of organizations with a de-facto AI lead haven't given that person the title.

The Pistoia Alliance reports that AI skills as a barrier jumped from 23 to 34% across pharma in 1 year (2024 to 2025).

The CEO is confident. The deputy is doing the actual work.

The deputy's first draft usually fails.

Why the first 3 AI strategy drafts don't land

A regulatory intelligence lead at a top global biotech told us his CEO had asked for an AI strategy memo 3 times in 2025. Each version came back too generic to land.

The first draft hedges: "We are exploring AI opportunities across the quality function." The board hears "we haven't started."

The second draft vendor cites: "We are piloting Vendor X's AI module." The board hears a brand name, not a strategy.

The third draft overpromises: "AI will reduce deviation closure time by 40%." The board asks for the baseline, and the deputy doesn't have one.

The fourth version, written with input from 3 quality directors, was finally cleared. It was 5 lines.

The 5-line AI strategy memo for quality and regulatory teams

Each line answers 1 question that the board will ask. Write them in order.

Line 1: What specific AI capability is the quality function using today?

Name the capability, not the vendor. Name the operator who runs it.

Example: "Our regulatory intelligence team uses AI-enabled search to summarise FDA enforcement actions for the supply chain monitoring group. The regulatory intelligence lead runs it daily."

1 sentence. Specific. The chief can read it aloud.

Line 2: What specific AI feature is being piloted next quarter?

Name the feature, the timeline, and the success criterion.

Example: "We're piloting AI-assisted gap assessment against FDA citation patterns for our 3 highest-risk manufacturing sites. Success criterion: the gap assessment surfaces findings that the manual review didn't, measured against the same site."

Timeline: Q3 2026.

The data-driven gap assessment method is a concrete example: 1 quality and regulatory team ran a manual assessment and found zero gaps, then ran a data-driven assessment and found 100 findings on the same site.

Line 3: What is the team explicitly not doing, and why?

This is the line most deputies skip. It's the line the board respects most.

Example: "We aren't using AI to draft or modify SOPs without quality unit review. The April 2026 Purolea warning letter cited exactly this practice under 21 CFR 211.22(c) and 21 CFR 211.100."

"Our position: AI assists, the quality unit approves."

An explicit "not doing" line anchored to a regulatory reason is stronger than 10 pages of "exploring."

Line 4: How is the team treating data integrity and human verification?

Reference 21 CFR Part 11 for electronic records and signatures. Refer to the verification chain: every AI-generated output in a regulated workflow undergoes a human review checkpoint before entering the QMS.

Example: "All AI outputs in regulated workflows go through quality unit review before entering the QMS. The audit trail is maintained under 21 CFR Part 11."

"No AI output bypasses the approval chain."

Line 5: What will the team know by the next board meeting, and what would change the plan?

This line signals the deputy is managing the AI strategy, not reacting to it.

Example: "By September, we'll know whether the AI-assisted gap assessment surfaces findings the manual review misses at our 3 pilot sites. If it does, we expand to the remaining 6 sites in Q4."

"If it doesn't, we re-evaluate the data source and the prompt architecture."

What to avoid in the AI strategy memo

3 patterns that kill the memo's credibility with the board.

Vendor names without verification. If the memo says "we are deploying Vendor X," the board will ask what due diligence the team ran. The vendor-evaluation questions for AI features in regulated workflows should be answered before a vendor name is entered into the memo.

Timelines that depend on a single pilot's success. If the entire AI strategy hinges on 1 pilot working, the board will ask what happens if it doesn't. Build the contingency into Line 5.

Any sentence that sounds like a vendor wrote it. "AI will revolutionize our quality function" is the sentence that gets the memo sent back for a fourth rewrite. The board wants clarity, not enthusiasm.

The chief of QA-RA's job: clarity, not AI expertise

The chief of QA-RA doesn't need to be an AI expert. The chief needs to read 5 lines aloud to the board without hedging.

The deputy's job is to write those 5 lines, so they're specific, defensible, and anchored to regulatory reality.

The chief's value to the board on this question is clarity. The deputy's value to the chief is making that clarity possible.

ZS's 2025 AI Trends Survey found 93% of pharma executives anticipate increased AI investment.

The question isn't whether AI is coming to quality. The question is whether the quality and regulatory team's answer to the board is concrete or generic.

The read-aloud test

When the 5 lines are written, read them aloud.

Ask: Would a VP Quality at Cipla feel respected reading this? If not, it's too generic.

Ask: Could the chief read this to the board without adding qualifiers? If not, it's too hedged.

Ask: Does every line name a specific capability, a specific timeline, or a specific regulatory anchor? If not, it's not ready.